Deep mutational scanning of target protein resistance to molecular glues
Interactions between proteins and small molecules are rich in nature – across organisms, tissues and cellular contexts they underly crucial biological functions in health and disease. One class of small biochemicals, molecular glu...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2015-64629-C2-1-R
CARACTERIZACION Y BLOQUEO MEDIANTE PEPTIDOS Y MOLECULAS PEQU...
303K€
Cerrado
MITiC
Molecules Inhibiting Translation in Cancer cells
185K€
Cerrado
POCKETSPPI
Discovering and exploiting hidden pockets at protein protein...
100K€
Cerrado
BAP
A dynamical view of binding affinity
166K€
Cerrado
DRUGPROFILBIND
Chemogenomic profiling of drug protein binding by shape ent...
2M€
Cerrado
PPIDESIGN
Thermodynamic basis of the inhibition of protein protein int...
217K€
Cerrado
Información proyecto DeepGlue
Duración del proyecto: 33 meses
Fecha Inicio: 2023-04-19
Fecha Fin: 2026-01-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Interactions between proteins and small molecules are rich in nature – across organisms, tissues and cellular contexts they underly crucial biological functions in health and disease. One class of small biochemicals, molecular glues (MGs), can selectively induce de novo protein-protein dimerization. Particularly in the context of targeted protein inhibition and degradation, MGs are praised as clinical alternatives to treating diseases driven by proteins that are otherwise pharmacologically intractable. Prominent examples like rapamycin, a MG used in the therapy of kidney tumours, illustrate a key research challenge, however: up until now, most MGs have been discovered by chance. Our limited understanding of their biophysical characteristics prevents us from rationally designing MGs, and from tracing drug resistance mechanisms by target proteins’ mutational escape during cancer evolution.
Here, I propose a scalable experimental strategy to determine the binding profiles of MGs to thousands of target protein mutants in parallel. To perform comparisons of the biophysical impact of mutations on distinct MG mechanisms, I have three major aims: 1.) to develop a deep mutational scanning assay to quantify MG-protein-protein complexation, 2.) to produce the first global atlas of resistance mutations for a classic MG system – rapamycin in complex with MTOR and FKBP12, and 3.) to characterise ABA, a plant hormone which induces heterodimer formation by extensive structural remodelling of only one of its target proteins.
DeepGlue will take place under the experienced supervision of Prof. Ben Lehner (CRG Barcelona), whose group has pioneered the use of deep mutagenesis to understand protein structures, dynamics and interactions. Within this environment, my action will be uniquely positioned to transcend the dynamic fields of Chemical Biology, Protein Biophysics and Cancer Evolution – aspiring to deliver fundamental insights that ultimately shape new and better therapies.